KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Debt Issuances (2016 - 2021)

Jazz Pharmaceuticals has reported Long-Term Debt Issuances over the past 8 years, most recently at $2.2 billion for Q4 2021.

  • Quarterly results put Long-Term Debt Issuances at $2.2 billion for Q4 2021, up 329.11% from a year ago — trailing twelve months through Dec 2023 was $2.2 billion (changed 0.0% YoY), and the annual figure for FY2024 was $980.8 million, changed.
  • Long-Term Debt Issuances for Q4 2021 was $2.2 billion at Jazz Pharmaceuticals, up from -$981.4 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for JAZZ hit a ceiling of $2.2 billion in Q4 2021 and a floor of -$981.4 million in Q4 2020.
  • Median Long-Term Debt Issuances over the past 3 years was -$91000.0 (2017), compared with a mean of $422.3 million.
  • Biggest five-year swings in Long-Term Debt Issuances: soared 30.0% in 2017 and later soared 329.11% in 2021.
  • Jazz Pharmaceuticals' Long-Term Debt Issuances stood at -$91000.0 in 2017, then crashed by 1078340.66% to -$981.4 million in 2020, then skyrocketed by 329.11% to $2.2 billion in 2021.
  • The last three reported values for Long-Term Debt Issuances were $2.2 billion (Q4 2021), -$981.4 million (Q4 2020), and -$91000.0 (Q4 2017) per Business Quant data.